JP2023550428A5 - - Google Patents

Info

Publication number
JP2023550428A5
JP2023550428A5 JP2023530225A JP2023530225A JP2023550428A5 JP 2023550428 A5 JP2023550428 A5 JP 2023550428A5 JP 2023530225 A JP2023530225 A JP 2023530225A JP 2023530225 A JP2023530225 A JP 2023530225A JP 2023550428 A5 JP2023550428 A5 JP 2023550428A5
Authority
JP
Japan
Prior art keywords
approximately
crystalline material
crystal
peaks
angles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550428A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/072510 external-priority patent/WO2022109598A1/en
Publication of JP2023550428A publication Critical patent/JP2023550428A/ja
Publication of JP2023550428A5 publication Critical patent/JP2023550428A5/ja
Pending legal-status Critical Current

Links

JP2023530225A 2020-11-19 2021-11-19 インテグリン阻害剤およびその使用 Pending JP2023550428A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063116042P 2020-11-19 2020-11-19
US63/116,042 2020-11-19
PCT/US2021/072510 WO2022109598A1 (en) 2020-11-19 2021-11-19 Integrin inhibitor and uses thereof

Publications (2)

Publication Number Publication Date
JP2023550428A JP2023550428A (ja) 2023-12-01
JP2023550428A5 true JP2023550428A5 (https=) 2024-11-26

Family

ID=81709878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530225A Pending JP2023550428A (ja) 2020-11-19 2021-11-19 インテグリン阻害剤およびその使用

Country Status (19)

Country Link
US (2) US12018025B2 (https=)
EP (1) EP4247472A4 (https=)
JP (1) JP2023550428A (https=)
KR (1) KR20230121761A (https=)
CN (1) CN116710169A (https=)
AU (1) AU2021381516A1 (https=)
CA (1) CA3173755A1 (https=)
CL (1) CL2023001418A1 (https=)
CO (1) CO2023006522A2 (https=)
CR (1) CR20230262A (https=)
CU (1) CU20230026A7 (https=)
DO (1) DOP2023000101A (https=)
EC (1) ECSP23045278A (https=)
IL (1) IL302651A (https=)
JO (1) JOP20230102A1 (https=)
MX (1) MX2023005889A (https=)
PE (1) PE20240114A1 (https=)
TW (1) TW202235417A (https=)
WO (1) WO2022109598A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
CN114173803A (zh) 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
CN120091811A (zh) * 2022-07-09 2025-06-03 普利安特治疗公司 整合素抑制剂及其与其它药剂组合的用途
WO2024155965A2 (en) * 2023-01-21 2024-07-25 Pliant Therapeutics, Inc. Biomarkers for use in integrin inhibitor therapy
WO2025072206A1 (en) * 2023-09-25 2025-04-03 Pliant Therapeutics, Inc. Integrin inhibitors for treatment of primary sclerosing cholangitis
US20250197393A1 (en) 2023-12-14 2025-06-19 Pliant Therapeutics, Inc. Integrin inhibitor and uses thereof
WO2025217571A1 (en) * 2024-04-12 2025-10-16 Pliant Therapeutics, Inc. Fixed dose combinations of integrin inhibitor with ppar agonists

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210033067A (ko) * 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
WO2015048819A1 (en) 2013-09-30 2015-04-02 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
WO2016145258A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
EP3509590A4 (en) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE
US10696672B2 (en) 2016-12-23 2020-06-30 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
MX394210B (es) 2017-02-28 2025-03-04 Morphic Therapeutic Inc INHIBIDORES DE INTEGRINA AVß6.
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
FI3761980T3 (fi) * 2018-03-07 2024-02-21 Pliant Therapeutics Inc Aminohappoyhdisteitä ja käyttömenetelmiä
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
WO2020016704A1 (ja) * 2018-07-20 2020-01-23 株式会社半導体エネルギー研究所 撮像パネル、撮像装置
WO2020047207A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibitors of (alpha-v)(beta-6) integrin
WO2020047239A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. INHIBITING αV β6 INTEGRIN
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
WO2020139379A1 (en) * 2018-12-28 2020-07-02 LunaPBC Community data aggregation, completion, correction, and use
US11730144B2 (en) * 2019-02-15 2023-08-22 Clean Bite, Llc Oral hygiene appliance
CN114173803A (zh) * 2019-04-08 2022-03-11 普利安特治疗公司 氨基酸化合物的剂型和方案
WO2021097338A1 (en) 2019-11-15 2021-05-20 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
CN115989235A (zh) * 2020-05-07 2023-04-18 普利安特治疗公司 使用氨基酸化合物治疗呼吸系统疾病的方法
TWI843503B (zh) * 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2022087224A1 (en) * 2020-10-21 2022-04-28 Cohbar, Inc. Method of treating fibrosis with a combination therapy
MX2023012794A (es) 2021-04-30 2023-12-15 Pliant Therapeutics Inc Regímenes de dosificación expandidos para inhibidores de integrina.
US20240350494A1 (en) 2021-09-03 2024-10-24 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
TW202329973A (zh) 2021-10-14 2023-08-01 美商普萊恩醫療公司 整合素抑制劑及其與其他藥劑併用之用途
JP2025518533A (ja) 2022-05-18 2025-06-17 プライアント・セラピューティクス・インコーポレイテッド インテグリン阻害剤の安定化

Similar Documents

Publication Publication Date Title
JP2023550428A5 (https=)
EP2968180B1 (en) Heterocyclic compounds and their uses
TW201010992A (en) Pharmaceutical composition
EP1492568A1 (en) Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor
CN104884057B (zh) 大麻素受体介导的化合物
CN105120844A (zh) 杂环化合物和其用途
JP2025511847A5 (https=)
JP2004537597A5 (https=)
RU2010133483A (ru) Новые кристаллические формы 4-{4-(2-адамантилкарбамоил)-5-третбутилпиразол-1-ил}бензойной кислоты
JP2009534373A5 (https=)
JP2025506098A5 (https=)
JPH07598B2 (ja) 光学的に純粋な化合物およびその製造方法
JP2004534802A (ja) 重水素化N−及びα−置換ジフェニルアルコキシ酢酸アミノアルキルエステル並びにこれを含有する医薬品
JP2014518281A (ja) 電位依存性ナトリウムチャネル遮断薬
JP7788128B2 (ja) 呼吸器疾患の治療のための化合物
JP2021529805A5 (https=)
KR20180008511A (ko) 제약 조성물
CN104721828A (zh) 一种改善晶体药物稳定性的药物组合物及其制备方法
CN108299279A (zh) 取代芳基胺醇化合物及其制备方法和用途
CN115443264A (zh) 新型化合物[2-(二甲基氨基)-2-苯基丁基]-3,4,5-三甲氧基苯甲酸酯4-甲基-2h-色烯-2-酮-7-基硫酸盐及其用途
HU228035B1 (en) Pharmaceutical compositions using terfenadine metabolites in combination with leukotriene inhibitors
JP2009519985A5 (https=)
KR20140092695A (ko) 발사르탄 함유 경구용 약학 조성물
CN101899056A (zh) 普拉格雷氢溴酸盐多晶型物及其制备方法
CN107405342A (zh) 一种含有二胺衍生物或其盐的固体药物组合物